VBI Vaccines (VBIV)
(Delayed Data from NSDQ)
$0.75 USD
-0.01 (-0.86%)
Updated Jul 9, 2024 03:59 PM ET
After-Market: $0.73 -0.02 (-2.16%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VBIV 0.75 -0.01(-0.86%)
Will VBIV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VBIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VBIV
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates
VBIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Other News for VBIV
VBI Vaccines Announces Results of Annual General Meeting
VBI Vaccines Shareholders Approve Board and Accountant
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Shows Promise in Glioblastoma Trial
VBI Vaccines announces new tumor response data from study of VBI-1901 in GBM